?? Exciting Update! Our NI-3201 manuscript published in Cancer Immunology Research ??
Light Chain Bioscience | Novimmune SA
Light Chain Bioscience – A brand of Novimmune SA
NI-3201 is a novel PD-L1xCD28 bispecific antibody (bsAb) designed to enhance T cell activity and boost anti-tumor function. By combining PD-L1 blockade with conditional CD28 costimulation, NI-3201 offers a dual mechanism of action that promotes robust T cell responses while maintaining safety. This approach has demonstrated significant promise, including:
? Enhanced T cell effector function in preclinical models
? Tumor regression and immunological memory induction
? Synergistic effects with T cell engagers
? Favorable tolerability and pharmacokinetics in non-human primates
The potential of NI-3201 to improve outcomes for patients resistant to current immunotherapies is compelling, and we’re excited to take this innovative therapy forward in the clinic.
We're thrilled to share that the NI-3201 program is on track to enter clinical trials by mid-2025.
You can access the full manuscript here.
#CancerImmunotherapy #CancerResearch #Biotech #Innovation #ClinicalTrials #ImmunoOncology #NI3201
Fostering strong partnerships by driving innovation & value creation for Drug discovery & development
1 个月Congratulations LCB team and Sara Majocchi . All the best for the clinical trials and excited to see NI-3201 make an impact for patients
Discovery Project Leader at Light Chain Bioscience
1 个月It has been an intense journey of discovery and collaboration. So rewarding to see our efforts being published in such a good journal. We're thrilled with this publication and look forward to continuing the development of NI-3201!